The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
Abstract
Following lymphocyte depletion, homeostatic mechanisms drive the reconstitution of lymphocytes. We prospectively studied this process in 16 patients for 1 year after a single pulse of treatment with Campath-1H, a humanised anti-CD52 monoclonal antibody. We observed two phases of lymphocyte reconstitution. In the first 6 months after treatment the precursor frequency and proliferation index of the patients' autologous mixed lymphocyte reaction increased; the depleted T cell pool was dominated by memory T cells, especially (CD4+)CD25high T cells, a putative regulatory phenotype; and there was a non-significant rise in peripheral mononuclear cell FoxP3 mRNA expression and fall in constitutive cytokine mRNA expression. In the later phase, from 6-to-12 months after Campath-1H, these changes reversed and there was a rise in ROG mRNA expression. However, total CD4+ numbers remained below 50% of pre-treatment levels at 12 months, perhaps reflecting a failure in homeostasis. This was not due to an impaired IL-7 response, as in rheumatoid arthritis, nor to a lack of IL-7 receptors, which are found on fewer human (CD4+)CD25high than naive cells. We speculate that CCL21 and IL-15 responses to lymphopaenia may be suboptimal in multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
CD4+CD25high Regulatory Cells in Human Peripheral Blood
Baecher-Allan, C., Brown, J. A., Freeman, G. J., & Hafler, D. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1245 · Cited by 1,859
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
Viglietta, V., Baecher-Allan, C., Weiner, H. L., & Hafler, D. A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031579 · Cited by 1,856
Reversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,634
Control of Homeostasis of CD8 + Memory T Cells by Opposing Cytokines
Ku, C. C., Murakami, M., Sakamoto, A., Kappler, J., & Marrack, P. (2000) · Science · doi:10.1126/science.288.5466.675 · Cited by 816
Tan, J. T., Ernst, B., Kieper, W. C., LeRoy, E., Sprent, J., & Surh, C. D. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020066 · Cited by 786
Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells
Becker, T. C., Wherry, E. J., Boone, D., Murali-Krishna, K., Antia, R., Ma, A., & Ahmed, R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020369 · Cited by 683
Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation
Goldrath, A. W., Bogatzki, L. Y., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.557 · Cited by 633
Cited by
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins
Veldhoen, M., Hirota, K., Westendorf, A. M., Buer, J., Dumoutier, L., Renauld, J.-C., & Stockinger, B. (2008) · Nature · doi:10.1038/nature06881 · Cited by 1,634
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationColes, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationThe safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
T cells in multiple sclerosis and experimental autoimmune encephalomyelitis
Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N., & Mills, K. H. G. (2010) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2010.04143.x · Cited by 945
for the Multiple Sclerosis Genetics Group, Gregory, S. G., Schmidt, S., Seth, P., Oksenberg, J. R., Hart, J., Prokop, A., Caillier, S. J., Ban, M., Goris, A., et al. (2007) · Nature Genetics · doi:10.1038/ng2103 · Cited by 657
Self-citationMechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Dutta, R., & Trapp, B. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.005 · Cited by 457
Reassessing B cell contributions in multiple sclerosis
Li, R., Patterson, K. R., & Bar-Or, A. (2018) · Nature Immunology · doi:10.1038/s41590-018-0135-x · Cited by 401
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
Hu, Y., Turner, M. J., Shields, J., Gale, M. S., Hutto, E., Roberts, B. L., Siders, W. M., & Kaplan, J. M. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03115.x · Cited by 335
Jones, J. L., Phuah, C.-L., Cox, A. L., Thompson, S. A., Ban, M., Shawcross, J., Walton, A., Sawcer, S. J., Compston, A., & Coles, A. J. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37878 · Cited by 297
Self-citationVaisman-Mentesh, A., Gutierrez-Gonzalez, M., DeKosky, B. J., & Wine, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01951 · Cited by 292
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis
Baker, D., Marta, M., Pryce, G., Giovannoni, G., & Schmierer, K. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.042 · Cited by 289
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings
Coles, A. J., Cohen, J. A., Fox, E. J., Giovannoni, G., Hartung, H.-P., Havrdova, E., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004354 · Cited by 277
Self-citationB cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A., & Muraro, P. A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00498-5 · Cited by 271
Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
Coles, A. J., Fox, E., Vladic, A., Gazda, S. K., Brinar, V., Selmaj, K. W., Skoromets, A., Stolyarov, I., Bass, A., Sullivan, H., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31824e8ee7 · Cited by 268
Self-citationDisease-modifying therapies and infectious risks in multiple sclerosis
Winkelmann, A., Loebermann, M., Reisinger, E. C., Hartung, H.-P., & Zettl, U. K. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.21 · Cited by 254
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Self-citationAlemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
Havrdova, E., Arnold, D. L., Cohen, J. A., Hartung, H.-P., Fox, E. J., Giovannoni, G., Schippling, S., Selmaj, K. W., Traboulsee, A., Compston, D. A. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004313 · Cited by 221
“Both mechanisms may be relevant to the durable efficacy of this drug.(4) Compared with the active treatment subcutaneous interferon b-1a (SC IFN-b-1a; Rebif; EMD Serono Inc.”
BackgroundImmune reconstitution syndrome and the thyroid
Weetman, A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.07.003 · Cited by 87
Anti-CD52 Therapy for Multiple Sclerosis: An Update in the COVID Era
Kasarello, K., & Mirowska-Guzel, D. (2021) · ImmunoTargets and Therapy · doi:10.2147/itt.s240890 · Cited by 11
Metadata
- Authors
- Cox, A. L., Thompson, S. A. J., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. S., & Coles, A. J.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2005-11
- Volume
- 35
- Issue
- 11
- Pages
- 3332-3342
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2106948231
- Cited by
- 291
- References
- 55
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.